TARS 250117 80.00P (TARS250117P80000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

TARS250117P80000

Watchlist

0.00
0.000.00%

15min DelayClose Jan 6 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

Express News | Tarsus Pharmaceuticals Inc : BofA Global Research Raises Price Objective to $74 From $68
ReutersJan 6 08:46 ET
The Zacks Analyst Blog Highlights ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDex
Zacks Dec 26, 2024 09:05 ET
4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow
Zacks Dec 24, 2024 11:00 ET
Oppenheimer Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $65
Moomoo NewsDec 20, 2024 13:31 ET · Ratings
Tarsus Pharmaceuticals Insider Lowered Holding By 16% During Last Year
Simply Wall StDec 16, 2024 07:05 ET
Guggenheim Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating
Moomoo NewsNov 29, 2024 12:31 ET · Ratings

Comments

Jerry Kronenberg

Nov 13, 2024 15:29

Columns Tarsus Pharmaceuticals Gains Some 15% After Hours on Better-Than-Expected Q3 Results

$Tarsus Pharmaceuticals (TARS.US)$ rose some 15% in after-hours trading Wednesday after the biotech reported a narrower-than-Q3 expected loss and better-than-forecast quarterly revenues.
TARS – which makes XDEMVY, a prescription eye drop to treat optical disease Demodex blepharitis – gained 14.5% to $53.25 shortly before 4:30 p.m. ET after unveiling a $0.61 Q3 loss, beating the $0.92 that analysts had reportedly f...

MMu

Oct 29, 2024 15:16

$Tarsus Pharmaceuticals (TARS.US)$ wonder which 2 pharmas are bidding for Tarsus!!

Stock_Drift

Oct 28, 2024 04:33

Pre Market Ticks. 5:32am 10/28

$Jet.AI (JTAI.US)$ $ProShares UltraShort Bloomberg Crude Oil ETF (SCO.US)$ $Phunware (PHUN.US)$ $ImmunityBio (IBRX.US)$ $Longeveron (LGVN.US)$ $BIOSIG TECHNOLOGIES INC (BSGM.US)$ $Tarsus Pharmaceuticals (TARS.US)$ $XTL Biopharmaceuticals (XTLB.US)$ $LENZ Therapeutics (LENZ.US)$ $TC BioPharm (TCBP.US)$ $Top Wealth Group Holding (TWG.US)$ $Healthcare Triangle (HCTI.US)$ $Pixie Dust Technologies(Delisted) (PXDT.US)$
📊⚡️📊

Jaguar8

Aug 8, 2024 15:17

NEWS

$Tarsus Pharmaceuticals (TARS.US)$
Tarsus Reports Second Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements
Tarsus Pharmaceuticals (NASDAQ: TARS) reported strong Q2 2024 financial results, with XDEMVY® net product sales reaching $40.8 million, a 65% increase from Q1.
Year-to-date sales totaled $65.5 million.
The company delivered over 37,000 bottles to patients in Q2 and achieved an impressive gross-to-net discount of 44%.
Tarsus expanded payer coverage, incl...

Moomoo AI

Mar 1, 2024 12:53

Analysts predict Tarsus Pharmaceuticals' growth to outpace the industry with a 5x annualised growth by 2024. The upgraded price target indicates an expected increase in the business's intrinsic value.

Analysts Are Upgrading Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) After Its Latest Results